Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05464329 · ClinicalTrials.gov registry record · Phase 1
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
A Phase 1 study of Large B-cell Lymphoma and High Grade B-Cell Lymphoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05464329 is a Phase 1 study of Large B-cell Lymphoma and High Grade B-Cell Lymphoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 24 participants, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05464329, a Phase 1 study of Large B-cell Lymphoma and High Grade B-Cell Lymphoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma. The hypothesis of this study is that mosunetuzumab can be safely combined with platinum-based salvage chemotherapy in this patient population, and that this approach may outperform chemoimmunotherapy approaches that instead incorporate rituximab retreatment. The enrolling physician's choice of the chemotherapy backbone will determine a patient's assigned study arm (Arm A = DHAX, Arm B = ICE). The two arms will accrue patients to phase Ib independently.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG DHAX
- DRUG ICE
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2029-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05464329
The ClinicalTrials.gov registry entry for NCT05464329 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Mosunetuzumab is the first listed.
NCT05464329 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05464329 about?
NCT05464329 is a clinical study titled "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma". This is a two-arm, open-label, phase Ib single-site study with expansion cohorts testing the addition of mosunetuzumab to intensive platinum-based salvage chemotherapy in patients with relapsed/refractory aggressive B cell lymphoma. The hypothesis of this study is that mosunetuzumab can be safely co...
What is the current status of trial NCT05464329?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-01-03. Estimated completion is 2029-10-16.
What conditions does trial NCT05464329 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma, High Grade B-Cell Lymphoma, Follicular Lymphoma Grade 3B, Transformed B-Cell Lymphoma.
What interventions are being tested in trial NCT05464329?
The interventions under investigation include: Mosunetuzumab (DRUG), DHAX (DRUG), ICE (DRUG).
Who is sponsoring clinical trial NCT05464329?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05464329 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
RECRUITING · Phase 1
-
Study of LYL314 in Aggressive Large B-Cell Lymphoma
RECRUITING · Phase 1
-
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RECRUITING · Phase 1
-
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.